Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

In vivo retention of (18)F-AV-1451 in corticobasal syndrome

Smith, Ruben LU ; Schöll, Michael LU ; Widner, Håkan LU ; van Westen, Danielle LU orcid ; Svenningsson, Per ; Hägerström, Douglas LU ; Ohlsson, Tomas ; Jögi, Jonas LU orcid ; Nilsson, Christer LU and Hansson, Oskar LU orcid (2017) In Neurology 89(8). p.845-853
Abstract

OBJECTIVE: To study the usefulness of (18)F-AV-1451 PET in patients with corticobasal syndrome (CBS).

METHODS: We recruited 8 patients with CBS, 17 controls, 31 patients with Alzheimer disease (AD), and 11 patients with progressive supranuclear palsy (PSP) from the Swedish BioFINDER study. All patients underwent clinical assessment, (18)F-AV-1451 PET, MRI, and quantification of β-amyloid pathology. A subset of participants also underwent (18)F-FDG-PET.

RESULTS: In the 8 patients with CBS, 6 had imaging findings compatible with the corticobasal degeneration pathology and 2 with typical AD pathology. In the 6 patients with CBS without typical AD pathology, there were substantial retentions of (18)F-AV-1451 in the motor cortex,... (More)

OBJECTIVE: To study the usefulness of (18)F-AV-1451 PET in patients with corticobasal syndrome (CBS).

METHODS: We recruited 8 patients with CBS, 17 controls, 31 patients with Alzheimer disease (AD), and 11 patients with progressive supranuclear palsy (PSP) from the Swedish BioFINDER study. All patients underwent clinical assessment, (18)F-AV-1451 PET, MRI, and quantification of β-amyloid pathology. A subset of participants also underwent (18)F-FDG-PET.

RESULTS: In the 8 patients with CBS, 6 had imaging findings compatible with the corticobasal degeneration pathology and 2 with typical AD pathology. In the 6 patients with CBS without typical AD pathology, there were substantial retentions of (18)F-AV-1451 in the motor cortex, corticospinal tract, and basal ganglia contralateral to the most affected body side. These patients could be clearly distinguished from patients with AD dementia or PSP using (18)F-AV-1451. However, cortical atrophy was more widespread than the cortical retention of (18)F-AV1451 in these CBS cases, and cortical AV-1451 uptake did not correlate with cortical thickness or glucose hypometabolism. These results are in sharp contrast to AD dementia, where (18)F-AV-1451 retention was more widespread than cortical atrophy, and correlated well with cortical thickness and hypometabolism.

CONCLUSIONS: Patients with CBS without typical AD pathology exhibited AV-1451 retention in the motor cortex, corticospinal tract, and basal ganglia contralateral to the affected body side, clearly different from controls and patients with AD dementia or PSP. However, cortical atrophy measured with MRI and decreased (18)F-fluorodeoxyglucose uptake were more widespread than (18)F-AV-1451 uptake and probably represent earlier, yet less specific, markers of CBS.

CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that (18)F-AV-1451 PET distinguishes between CBS and AD or PSP.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Journal Article
in
Neurology
volume
89
issue
8
pages
9 pages
publisher
Lippincott Williams & Wilkins
external identifiers
  • pmid:28754841
  • wos:000407992500045
  • scopus:85027875368
ISSN
1526-632X
DOI
10.1212/WNL.0000000000004264
language
English
LU publication?
yes
id
e8e03297-f85c-4d1d-bf80-f8a1c3a39879
date added to LUP
2017-08-25 13:25:26
date last changed
2024-05-26 21:14:26
@article{e8e03297-f85c-4d1d-bf80-f8a1c3a39879,
  abstract     = {{<p>OBJECTIVE: To study the usefulness of (18)F-AV-1451 PET in patients with corticobasal syndrome (CBS).</p><p>METHODS: We recruited 8 patients with CBS, 17 controls, 31 patients with Alzheimer disease (AD), and 11 patients with progressive supranuclear palsy (PSP) from the Swedish BioFINDER study. All patients underwent clinical assessment, (18)F-AV-1451 PET, MRI, and quantification of β-amyloid pathology. A subset of participants also underwent (18)F-FDG-PET.</p><p>RESULTS: In the 8 patients with CBS, 6 had imaging findings compatible with the corticobasal degeneration pathology and 2 with typical AD pathology. In the 6 patients with CBS without typical AD pathology, there were substantial retentions of (18)F-AV-1451 in the motor cortex, corticospinal tract, and basal ganglia contralateral to the most affected body side. These patients could be clearly distinguished from patients with AD dementia or PSP using (18)F-AV-1451. However, cortical atrophy was more widespread than the cortical retention of (18)F-AV1451 in these CBS cases, and cortical AV-1451 uptake did not correlate with cortical thickness or glucose hypometabolism. These results are in sharp contrast to AD dementia, where (18)F-AV-1451 retention was more widespread than cortical atrophy, and correlated well with cortical thickness and hypometabolism.</p><p>CONCLUSIONS: Patients with CBS without typical AD pathology exhibited AV-1451 retention in the motor cortex, corticospinal tract, and basal ganglia contralateral to the affected body side, clearly different from controls and patients with AD dementia or PSP. However, cortical atrophy measured with MRI and decreased (18)F-fluorodeoxyglucose uptake were more widespread than (18)F-AV-1451 uptake and probably represent earlier, yet less specific, markers of CBS.</p><p>CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that (18)F-AV-1451 PET distinguishes between CBS and AD or PSP.</p>}},
  author       = {{Smith, Ruben and Schöll, Michael and Widner, Håkan and van Westen, Danielle and Svenningsson, Per and Hägerström, Douglas and Ohlsson, Tomas and Jögi, Jonas and Nilsson, Christer and Hansson, Oskar}},
  issn         = {{1526-632X}},
  keywords     = {{Journal Article}},
  language     = {{eng}},
  month        = {{08}},
  number       = {{8}},
  pages        = {{845--853}},
  publisher    = {{Lippincott Williams & Wilkins}},
  series       = {{Neurology}},
  title        = {{In vivo retention of (18)F-AV-1451 in corticobasal syndrome}},
  url          = {{http://dx.doi.org/10.1212/WNL.0000000000004264}},
  doi          = {{10.1212/WNL.0000000000004264}},
  volume       = {{89}},
  year         = {{2017}},
}